Astrotech reports Q1 FY2023 revenue of $38K, authorizes $1M share repurchase

ASTROTECH Corp

Revenue $38K for Q1 FY2023, down from prior year due to shift from ETD to AgLAB-1000-D2 commercialization.
Cash and liquid investments total $48.9M, supporting R&D, organic growth, and potential acquisitions.
Board authorized $1M share repurchase program from Nov 17, 2022 through Nov 17, 2023.
BreathTech subsidiary contracts clinical research firm to collect breath samples; BreathTest-1000 shows discrimination ability.
AgLAB-1000-D2 field trials promising; first production run started and sales efforts underway.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

ASTROTECH Corp reported first quarter of fiscal year 2023, which ended September 30, 2022 results: revenue $38 thousand.

Period: first quarter of fiscal year 2023, which ended September 30, 2022
Revenue: $38 thousand
Result: reported results

Exact text from the filing

Revenue for the quarter totaled $38 thousand and was mainly related to ongoing maintenance services and sales of consumables for the TRACER 1000TM explosive trace detector (ETD).

View on SEC.gov

47 earnings releases filed in the last 30 days. Browse all earnings releases →

ASTROTECH Corp filing history →

Source: SEC EDGAR

accession 0001437749-22-026776

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.